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1 EXECUTIVE SUMMARY 
BACKGROUND 
Researchers at the University of Brighton have studied the underpinning biology and physiology of 
the ageing bowel which has implicated age-related changes in TNF-α expression as a cause of 
changes in faecal output in healthy older mice. Initial studies have shown that a marketed TNF-α 
antagonist, Etanercept (Pfizer and others) can reverse the effects of age-related constipation in this 
mouse model. This type of drug is currently prescribed for rheumatoid arthritis and ulcerative colitis, 
and is a biological molecule which is infused via injection and is expensive to manufacture. Although 
TNF-α antagonists are safe for chronic usage in elderly patients, the drug can suppress the immune 
system and these factors need to be taken into account when prescribing these drugs for the long-
term treatment of the elderly. 
Constipation is experienced by both humans and animals, so this opportunity is relevant to both 
human and animal health. It is not a well-defined disease entity, but a general collection of 
symptoms. Constipation is considered chronic if it is present for a total of at least 12 weeks (non-
consecutively) in any one year period. Chronic constipation can significantly affect an individual’s 
quality of life and may be associated with significant health care costs. The aetiology of constipation 
is usually multifactorial, and may include diet, structural issues, other disease conditions and 
medications. Primary forms also occur, but are less common. About 20% of the general population 
experiences problems with constipation during their life time, with elderly people and women being 
more commonly affected. Since many people self-treat, only a small number of patients seek 
medical help. 
MARKET CHARACTERISTICS – HUMAN HEALTH 
The global constipation treatment market was estimated by BCC Research to be US$12.58 billion in 
2016, growing at a healthy CAGR of 7.1% to an estimated US$22.93 billion by 2025. Within the 
overall market for constipation medication, the largest segment is for laxatives. Research and 
Markets suggest that over 65% of the $1.89 billion chronic idiopathic constipation market is 
captured by OTC laxative drugs. Other treatment options are lifestyle changes (particularly diet, fluid 
intake and exercise), non-pharmacological consumer health market products and prescription 
pharmaceuticals. In the UK NICE advises diet and lifestyle changes initially, followed by drug 
treatment with different types of laxative. Of the prescription drugs, Linaclotide led sales in 2016, 
ending Amitiza’s dominance of the market, which achieved sales of $420million in 2016. Sodium 
picosulfate and lactulose achieved third and fourth place respectively. There is also a pipeline of new 
drugs, several of which are close to the market, with earlier stage development mainly focused on 
drugs which act on 5-HT4R. 
MARKET CHARACTERISTICS – ANIMAL HEALTH 
Companion animals and horses are known to suffer from constipation and within species, 
prevalence is higher in certain breeds. The causes depend on the species and any underlying 
conditions that may be known to contribute to the condition. 
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According to an industry trade group, the global market for animal medicines is about one-fortieth 
of that spent on human medicines, but it has not been possible to find a breakdown of the market 
size for constipation treatments in animals. The rise in pet ownership is driving a rise in the 
companion animal pharmaceutical product market, with total U.S. pet industry expenditures 
projected by the American Pet Products Association to rise by almost $3 billion to just over $69 
billion in 2017. As for humans, most treatments are focused on non-pharmacological approaches in 
the first instance, followed by laxatives and other medications depending on the exact type of gastric 
distress experienced. There is generally a lack of available products to treat chronic constipation and 
off-label use for drugs approved for humans are an option for vets. Chronic constipation that is 
unresponsive to medical management may be treated by surgical therapy with associated risks and 
significant cost implications. 
COMPETITIVE POSITION 
Most healthcare organizations still consider standard laxatives as the first line of treatment for 
constipation as they are cheap and widely available. For example, a study comparing the costs of 
laxatives in Canada in 2014 revealed laxative costs of CA$13-24/month, while prescription only 
medicines cost from $80/month to $240/month. In contrast, the cost of TNF-alpha antagonist 
Etanercept in the UK is between £328 - £715 per month, depending on the distributor and the type 
of injection delivery system. 
Given the availability of low-cost, very safe, and relatively efficacious alternatives, a high-cost, 
injectable medicine with the potential for severe side effects and which causes a reduction in 
immune competence would rank very low down the list of treatment options for what is a 
distressing, but not life-threatening condition. We would therefore expect the market share for a 
treatment of this nature to be a very small segment of the overall market. 
IP LANDSCAPE 
An examination of the patent landscape suggests that there is a fairly low interest in patents which 
address the treatment of chronic constipation in the elderly. The searches carried out have not 
identified any patents which relate to treatment of constipation directly with anti-TNF-α drugs. 
However, as constipation is a side-effect of conditions such as ulcerative colitis which is treated with 
anti-TNF-α drugs, this additional use of this class of drugs may have been considered obvious.  
There may still be an opportunity for the team to develop an intellectual property position around 
novel compounds or novel delivery mechanisms targeting anti-TNF-α drugs for constipation. The 
patent literature suggests that investigation of treatments which combine TNF-α antagonism with 
targeted delivery mechanisms for constipation is not an active area of interest, either in the 
pharmaceutical companies or amongst academics. This suggests that this is not viewed as a 
commercially promising approach. 
STAKEHOLDER FEEDBACK 
Primary research with clinicians and companies suggests that for human health, the treatment 
concept seems to fall between two different types of pharmaceutical intervention. Chronic 
constipation is generally seen as an indication that is not of high interest to the large prescription 
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medicine pharmaceutical companies, which view it as out of scope. It is of more interest to their 
consumer health divisions, but these are focused on over the counter remedies, and for these 
medicines injectable products with high cost would never be possible either from a market 
acceptance or a regulatory standpoint. 
Limited clinical feedback suggests that there are existing treatments available or in the pipeline 
which are very safe and efficacious. Whilst the mechanistic concept was interesting, the costs and 
risks of infection were considered to rule out use of the existing anti-TNF drugs as a viable option for 
the elderly patient group. 
There was a more open-minded attitude within animal health, where an injectable product was seen 
as less of a disadvantage, and there are clear unmet medical needs. However, the biggest problems 
(such as idiopathic megacolon in cats and ileus in horses) do not appear to be clearly linked to age, 
and so may be acting through a different mechanism from the one investigated by the team in their 
aged mouse model. Cost was consistently raised as an issue in animal health, particularly as the 
common treatments, such as laxatives, are very cheap and often efficacious. 
SWOT ANALYSIS 
STRENGTHS WEAKNESSES 
• Novel approach, that does not appear to be 
actively researched by others 
• Potential to be curative, rather than just treat the 
symptoms 
• Large market for treatment of constipation 
• Existing treatments are generally cheap, safe and 
efficacious 
• Exemplar treatment used by the team has 
drawbacks in terms of cost, route of administration 
and side effects 
• Early stage of development, and a new molecule is 
likely to be needed to enter this market 
• Regulatory hurdles for an OTC product are high 
• Little interest identified in pharmaceutical 
companies for new approaches to constipation 
OPPORTUNITIES THREATS 
• Additional data on the effectiveness of etanercept 
compared with OTC laxatives in the Brighton 
mouse model could help to demonstrate superior 
activity for this approach 
• Identification of small molecule anti-TNF drugs 
would open up the potential for OTC drugs 
• Lack of registered IP protection is likely to 
significantly impact on the ability to gain traction 
with pharmaceutical companies 
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2 BACKGROUND 
Through BBSRC funded research, researchers at the University of Brighton have studied the 
underpinning biology and physiology of the ageing bowel which has implicated age-related changes 
in TNF-α expression as a cause of changes in faecal output in healthy older mice. This provides a new 
model of constipation in elderly animals and humans which may be used to understand the 
underlying biology, leading eventually to novel methods of relieving this challenging condition. Initial 
studies using a marketed TNF-α antagonist, Etanercept (Pfizer and others), for treating ulcerative 
colitis (UC) and rheumatoid arthritis (RA) can reverse the effects of age-related constipation in this 
mouse model. Both UC and RA are chronic debilitating conditions that can affect older people and 
the drugs are safe in this age group, but as the drug can suppress the immune system the severity of 
the condition and how much it impacts on the life of the patient are clearly factors that need to be 
taken into account when prescribing these drugs for the long term treatment of the elderly. 
To further quantify the market opportunity for effective management of age-related chronic 
constipation, the University successfully applied for BBSRC Pathfinder support to: 
• Provide a detailed understanding of the current market and competitive landscape for the 
management of constipation in the elderly and in ageing companion animals, using 
secondary research and primary interviews with stakeholders from different market 
segments (animal health, consumer health, pharmaceuticals). This assessment will also 
include identification of competing products and treatment approaches, as well as 
regulatory constraints and hurdles 
• Identify potential partners in the animal health/consumer health/pharmaceutical industries, 
and understanding their requirements through direct interviews 
• Examine the IP landscape to identify technology developments in this market, in order to 
develop an appropriate IP strategy 
• Identify a development plan that will provide proof-of-concept validation data required to 
attract the right partner to commercialise the technology 
• Identify an appropriate route to commercialisation that may be supported by a full Follow 
on Fund application.  
IP Pragmatics Limited (IPP) was appointed by the University to carry out this market and patent 
analysis work and this report summarises the findings from this study. 
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3 METHODOLOGY 
In compiling this report IPPL used the following methods: 
• Discussions with scientists and business managers at the University to gather background 
information on the technology, plans for its development and any existing commercialisation 
links with potential partners. 
• Collation of secondary market information from published sources via Internet searches and 
via use of IPP’s proprietary market report databases that it subscribes to from sources such 
as BBC Research, GlobalData, Frost & Sullivan, Marketline, Business Insights and Beauhurst 
(UKFunders). 
• Patent database searches using open sources and proprietary Derwent Innovation patent 
analysis databases and software from Clarivate Analytics. 
• Direct primary market information gathered from healthcare and veterinary professionals 
and companies and organisations operating in the field and within IPPL’s personal business 
contact networks. 
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4 THE MARKET POTENTIAL AND OPPORTUNITIES 
Chronic constipation not only affects humans but also affects a number of animal species. 
4.1 THE MARKET FOR TREATING CONSTIPATION IN HUMANS 
Constipation is not a well-defined disease entity, but a general term used to describe the difficulties 
that a subject experiences with moving their bowels. Diagnosis requires the collection of data such 
as family history, medications (especially those that are known to slow down the gastrointestinal 
transit) and comorbidities, together with a physical examination that includes digital rectal 
examination. In an effort to improve diagnosis of chronic constipation, an International group of 
experts proposed symptom-based criteria known as the Rome criteria1: 
ROME III CRITERIA 
1. A patient must have >2 of the following symptoms over the preceding 3 months: 
• Straining during at least 25 % of defecations 
• Lumpy or hard stools in at least 25 % of defecations 
• Sensation of incomplete evacuation for at least 25 % of defecations 
• Sensation of anorectal obstruction/blockage for at least 25 % of defecations 
• Manual maneuvers to facilitate at least 25 % of defecations (e.g., digital evacuation, support 
of the pelvic floor) 
• Fewer than three defecations per week 
2. Loose stools are rarely present without the use of laxatives 
3. There are insufficient criteria for irritable bowel syndrome 
Constipation is considered chronic if it is present for at least 12 weeks (in total, not necessarily 
consecutively) during the previous year. Chronic constipation can significantly affect an individual’s 
quality of life and may be associated with significant health care costs.2 
The aetiology of constipation is usually multifactorial and a component of a wider complex clinical 
picture (secondary constipation). However, primary forms (idiopathic, functional) are also 
diagnosed: 
PRIMARY FORMS 
There are 3 types of primary constipation: 
1. Slow transit constipation (STC): characterized by infrequent bowel movements where 
altered colonic motility plays a major role. It may also be associated with several endocrine 
                                                          
1
 Schuster, B. Constipation in older adults. Can. Fam. Physician (2015)  
2
 https://emedicine.medscape.com/article/184704-overview#a2 
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and metabolic disorders such as hypothyroidism, hypercalcemia, porphyria or diabetes 
mellitus. STC is seen more frequently in female patients. 
2. Pelvic floor dysfunction: characterized by a lack of coordination between abdominal muscles 
contraction and pelvic floor muscle relaxation on straining. 
3. Normal transit constipation (NTC): characterized by difficulty in evacuating bowels. Patients 
sometimes meet the criteria for IBS with constipation (IBS-C). The primary difference 
between chronic constipation and IBS-C is the prominence of abdominal pain or discomfort 
in IBS. Patients with NTC usually have a normal physical examination. NTC is the most 
common subtype. 
SECONDARY FORMS 
Secondary forms of constipation can be caused by a variety of issues. The most common causes of 
secondary constipation are3 
Category Examples 
Diet Inadequate water intake 
Inadequate fibre intake 
Over consumption of coffee, tea or alcohol 
Ignoring the urge defecate 
Reduced levels of exercise 
Structural Anal fissures 
Thrombosed haemorrhoids 
Colonic strictures 
Obstructing tumours 
Volvulus 
Idiopathic megarectum 
Systemic conditions Endocrinologic and metabolic disorders: Hypercalcemia, 
hyperparathyroidism, hypokalemia, hypothyroidism, pregnancy, and 
diabetes mellitus (constipation is the most common gastrointestinal problem 
affecting the diabetic population) 
Neurologic disorders: Stroke, Hirschsprung disease, Parkinson’s disease, 
multiple sclerosis, diabetic autonomic neuropathy, spinal cord lesion, head 
injury, cerebrovascular accident, dementia, Chagas disease, and familial 
dysautonomia 
Connective-tissue disorders: Scleroderma, amyloidosis, and mixed 
connective-tissue disease 
Other disorders Depression 
Eating disorders 
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Medicines Medications that may contribute to constipation include: 
Anabolic steroids 
Antacids containing aluminium and calcium 
Anticholinergics (eg, benztropine and trihexyphenidyl) 
Anticonvulsants 
Antidepressants (eg, tricyclic antidepressants and monoamine oxidase 
inhibitors (MAOIs) 
Antihistamines 
Anti-Parkinsonian drugs (eg, dopaminergic drugs) 
Calcium channel blockers (eg, verapamil) 
Cholestyramine and stimulant laxatives (long-term use) - Although laxatives 
are frequently used to treat constipation, chronic laxative use becomes 
habituating and may lead to the development of a dilated atonic laxative 
colon, which necessitates increasing laxative use with decreasing efficacy 
Diuretics (e.g, furosemide, hydrochlorothiazide) 
Inadequate thyroid hormone supplementation  
Metals (eg, iron and bismuth) 
Nonsteroidal anti-inflammatory drugs (NSAIDs; eg, ibuprofen and diclofenac) 
Opioids (eg, codeine and morphine) 
Psychotropic drugs3 
Sympathomimetics (eg, pseudoephedrine) 
4.1.1 MARKET SIZE 
About 20% of the general population experiences problems with constipation during their life time4 
with elderly people and women (M/F ratio: 1:2-3) being mostly affected.  
In North America alone, chronic constipation affects approximately 63 million people. Worldwide, 
approximately 12% of people suffer from self-defined constipation. People in the Americas and the 
Asian Pacific suffer twice as much as their European counterparts.  
The prevalence of constipation increases with age; studies have suggested that 30-40% of adults in 
the US over 65 years of age have cited constipation as a problem. In population studies of this age 
group, 26% of women compared to 16% of men considered themselves to be constipated, while in 
an 84 year-old subgroup of patients, the proportion of sufferers increased to 34% in women and 
26% in men1 . Since many people self-treat, only a small number of patients seek medical help. 
                                                          
3
 Uher R et al, Adverse reactions to antidepressants (2009) British Journal of Psychiatry 
4
 BCC Report: GI Therapeutics and Diagnostics: Technologies and Global Markets (PHM046C Sept 2016) 
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The global constipation treatment market was worth an estimated US$12.58 billion in 2016, with the 
US market worth $5.84 billion in 2017. The global constipation treatment market to forecast exhibit 
a healthy CAGR of 7.1%, estimating it to reach an overall valuation of US$22.93 billion by 20255. 
Within the total market, the largest market segment is for laxatives. The prescription laxative market 
is predicted to hit almost $2.0 billion in 2021 according to BCC Research. This represents a 21.1% 
CAGR from the $753.2 million estimated for 2016. During the forecast period, the U.S. market is 
expected to grow significantly. In 2021, the U.S. market is forecast to reach almost $1.7 billion, for a 
five-year CAGR of 23.1% from 2016: 
 
4.1.2 GEOGRAPHICAL DISTRIBUTION 
Geographically, North America is the leading market for constipation treatments, for all disease 
segments as well as in functional/idiopathic constipation. The North America constipation market is 
estimated to be worth $9.98billion by the end of 2025. Europe follows as the second largest market 
currently. Growth regions include Asia Pacific with Japan, India, and China identified as three 
emerging markets for constipation treatment. Mexico and Brazil are considered high potential 
growth markets in Latin America because of improvement of medical infrastructure.6  
4.1.3 MARKET OPPORTUNITIES 
CHRONIC IDIOPATHIC CONSTIPATION 
Where the cause of constipation is unknown or unclear it is classed as idiopathic constipation. The 
global chronic idiopathic constipation (CIC) treatment market is expected to reach $2.86 billion by 
2025 from $1.89 billion in 2017 according to Research and Markets. Their research suggests that 
over 65% of the CIC market is captured by the OTC drugs segment while a Transparency Market 
Research report estimates that only 12% are medically diagnosed with idiopathic constipation. 
                                                          
5
 Transparency Market Research: Global Constipation Treatment Market, 2017 
6
 Transparency Market Research Report: Chronic Idiopathic Constipation (CIC) Treatment Market - Global 
Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024 
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In the elderly, chronic constipation is a frequently reported bowel symptom with considerable 
impact on quality of life and health expenses. Constipation is not a physiologic consequence of 
normal aging, but medications, underlying diseases, and rectal sensory-motor dysfunction may all 
contribute to its increased prevalence in older adults. Furthermore, there are psychosocial and 
behavioral factors that may predispose the elderly to develop constipation, such as decreased 
mobility and inadequate calorific intake. Therefore in the elderly there is usually more than one 
etiologic mechanism, requiring a multifactorial treatment approach7. 
OPIOID INDUCED CONSTIPATION 
The number of patients suffering from opioid induced constipation is increasing across the globe as 
the number of people consuming opioid drugs increases; around 40% of patients are thought to 
experience opioid-induced constipation. According to the American Academy of Pain Medicine 
approximately 100 million people were suffering from OIC in 2013 in the US and consumes close to 
80% of the global supply of opioids.  
Severe chronic constipation is a major side effect of consumption of opioid and because sufferers 
are resistant to traditional laxatives, novel targeted therapies are prescribed. Research conducted by 
Transparency Market Research estimates that the global market for opioid induced constipation 
treatment is expected to reach US$4.8 billion by 2023, from $731.2 million in 2016 (CAGR of 31.2% 
from 2015 to 2023). By the end of 2023, North America alone is expected to generate US$4.05 
billion of the global revenue from opioid induced constipation treatments.8  
IBS WITH CONSTIPATION 
Common triggers for irritable bowel syndrome include food, hormones, stress, and other illness such 
as gastroenteritis and over growth of intestinal bacteria. Long term management is required for IBS 
as it is a chronic condition. IBS mostly occurs in people below the age of 45 and is twice more 
prevalent in women compared to men. In the US there is approximately an 11% prevalence rate of 
irritable bowel syndrome. IBS can be classified into 3 types based on predominant symptoms – IBS-D 
where diarrhea is the predominant symptom, IBD-C where constipation is the predominant 
symptom, and IBS-M with mixed symptoms. Around 35% IBS patients are likely to be affected with 
constipation. 
Treatment is mainly focused on relieving the symptoms of IBS so that patients can live a normal life. 
Mild irritable bowel syndrome can be managed by changes in lifestyle and diet, whereas moderate 
to severe IBS requires medication. First line treatment for all types of IBS include dietary 
modification, exercise, counselling, and avoiding the triggers. If these treatment options do not help, 
                                                          
7
 De Giorgio et al. (2015) BMC Gastroenterology 15:130  
8
 Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, 
and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 
2015 - 2023) 
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in IBS-C laxatives and fiber supplements are used. However, overall relief provided by these 
treatments are not satisfactory and usually lead to adverse effects. 
4.1.4 TREATMENT 
The market for constipation therapeutics is divided into 3 main segments: non-pharmacological 
consumer health market products, OTC laxatives and prescription pharmaceuticals. Specific drugs 
are also indicated for opioid induced constipation. 
NON-PHARMACOLOGICAL TREATMENTS 
Non-pharmacological treatment (which consists of diet and lifestyle modifications) and management 
of medication-induced causes, are considered first steps in the effective management of 
constipation, including in the older population. Modifications such as increasing intake of fluids and 
fibres are recommended prior to initiating other forms of therapy, such as laxatives. 
Ingestion of natural fibre sources from fruits, vegetables, and cereals, is nutritionally superior to 
purified fibre supplements. However, as advising patients to eat more fruits and vegetables is 
frequently unsuccessful, patients may prefer a soluble fibre supplement, such as wheat, psyllium 
(both naturally occurring), methylcellulose (semi-synthetic), or calcium polycarbophil (synthetic). 
These agents can also be regarded as bulking forming laxatives by increasing stool bulk by holding 
liquid in the gut.  
Faecal flora changes markedly with age but it is not known whether this is a cause or the effect of 
constipation. Probiotics, such as bioyoghurts and dietary supplements are a common treatment 
because of their lack of side effects and absence of inference with medication. 
LAXATIVE AND PHARMACOLOGICAL TREATMENTS 
According to BCC Research it is estimated that more than $800 million is spent on over-the-counter 
laxatives in the United States every year5. However, only a minority of total patients (approximately 
25%) use medical treatments. 
In the older population, the use of laxatives must be individualized with special attention paid to 
cardiac and renal co-morbid conditions, drug interactions, and side effects. Laxative compounds 
commonly used to treat chronic constipation include: 
Type Laxative agent Agents contraindicated, or used with 
caution in elderly
9
 
Bulk-forming 
laxatives 
Natural fibres (e.g. psyllium/ispaghula 
husk)  
Avoid in patients with cognitive impairment, 
fluid restrictions, dysphagia and those who 
                                                          
9
 Kosar L, Schuster B. RxFiles drug comparison charts. 10th ed. Saskatoon, SK: RxFiles; 2014. Constipation and 
laxatives 
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Type Laxative agent Agents contraindicated, or used with 
caution in elderly
9
 
Semi-synthetic fibres (e.g. 
methylcellulose) 
Synthetic fibres (e.g. Polycarbophil) 
are bedridden 
Osmotic laxatives Magnesium hydroxide, magnesium 
citrate, magnesium sulfate, sodium 
phosphate. 
Polyethylene glycols with or without 
electrolytes (e.g. Macrogol, Miralax) 
Avoid in individuals with cardiac or renal 
dysfunction, dehydration or serious 
electrolyte dysfunction 
Osmotic: 
Disaccharides and 
alditols 
Lactulose (Constulose), sorbitol.  
Emollients laxatives Paraffin oil, docusate sodium (Colace) Docusate: lack of evidence for prevention 
and treatment of constipation (ie, no harm, 
but ineffective) 
Oral mineral oil should be avoided for older 
adults owing to concerns about aspiration 
Stimulant laxatives diphenylmethane derivatives 
(bisacodyl, sodium picosulfate) 
Anthraquinones (senna, aloe, cascara) 
Sodium picosulfate used with caution 
 
Targeted drug treatment options for laxative-resistant, chronic constipation10: 
Drug Mechanism of 
action 
Effect Marketing approval 
Lubiprostone, 
Mallinckrodt 
(Amitiza) 
Type 2 chloride 
channel activator 
Chloride secretion with 
distension of intestinal 
walls and activation of 
peristalsis and 
acceleration of intestinal 
transit. 
Approved for chronic idiopathic 
constipation; constipation caused by 
irritable bowel syndrome (IBS-C) in 
women; and opioid-induced 
constipation in patients with 
chronic, non-cancer pain. 
Linaclotide, 
Ironwood Pharma 
(Linzess, 
Constella) 
Guanylate cyclase C 
receptor peptide 
agonist 
Increase of secretion of 
chloride, bicarbonate and 
water into intestinal 
lumen. 
Approved for chronic idiopathic 
constipation and constipation 
caused by irritable bowel syndrome 
(IBS-C). In development for opioid 
induced constipation 
Plecanatide, Guanylate cyclase C Activation of peristalsis Approved in the US for chronic 
                                                          
10
 Will be a mix of BCC and Global Data…. 
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Drug Mechanism of 
action 
Effect Marketing approval 
Synergy Pharma 
(Trulance) 
receptor agonist and acceleration of 
intestinal transit. 
idiopathic constipation in adults 
Prucalopride, J&J 
(Resolor) 
5-HT4 serotonin 
receptor agonist 
Excitatory activity of 
neurons of the myenteric 
plexus, stimulates 
intestinal motility. 
EU approved for chronic 
constipation; not yet approved in US 
Cisapride (Alzide) 5-HT4 serotonin 
receptor agonist 
 Approved in India only 
Tegaserod, 
Novartis (Xavena, 
Zelmac) 
5-HT4 serotonin 
receptor agonist 
 Approved in South Africa and South 
Korea only; withdrawn from the US 
market 
Elobixibat, AZ 
(Goofice) 
Enantiomer of 1,5-
benzothiazepine. 
Bond and inhibits the ileal 
bile acid transporter. 
Approved in Japan only 
Laxatives most commonly used in clinical practice in the US include milk of magnesia, lactulose, 
senna compounds, bisacodyl and polyethylene glycol (PEG) preparations11. There is limited evidence 
to guide the order in which the agents should be used in older adults, but often a bulk-forming agent 
would be initiated first (except in those who are bedridden, are cognitively impaired, or have other 
contraindications). For patients with a contraindication or lack of response to a bulking agent, an 
osmotic agent, such as PEG 3350 or lactulose, is indicated12.  
In the UK NICE has published a clinical knowledge summary on chronic constipation in adults as a 
practical resource for primary care professionals (it is not formal NICE guidance), which also advises 
drug treatment with laxatives if the individual has ongoing symptoms despite having made changes 
to their diet and lifestyle, and investigating the role of any drugs that may be contributing to or 
causing constipation. Bulk-forming laxatives are usually suggested initially, and if symptoms remain, 
a switch to an osmotic laxative, such as a macrogol is recommended, followed by lactulose if 
macrogol is ineffective or not tolerated. Drug treatment with prucalopride or lubiprostone may then 
be recommended if at least two laxatives from different classes have been tried at the highest 
tolerated recommended doses for at least 6 months. 
Of the prescription drugs, Linaclotide led sales in 2016, ending Amitiza’s dominance of the market, 
which achieved sales of $420million in 2016. The laxatives, sodium picosulfate and lactulose, 
achieved third and fourth place respectively. 
                                                          
11
 Rao SS. Constipation: Evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol 
Clin North Am. 2007 
12
 Schuster B et al, (2015) Constipation in older adults. Can Fam Physician. 61(2) 
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Sales of linaclotide are on track to exceed $1 billion in the US alone by 2020. In 2021, linaclotide is 
expected to achieve blockbuster sales of $1.2 billion in the U.S., France, Germany, Italy, Spain, the 
U.K. and Japan. 
TREATMENT FOR OPIOID INDUCED CONSTIPATION 
A new class of drugs acting peripherally as mu-opioid receptor antagonists (PAMORAs) are approved 
to provide relief from constipation associated with chronic opioid use. They selectively displace 
opioids from mu-opioid receptors outside the CNS, decreasing the constipating effects of opioids: 
Drug name (Brand name) Company Marketing approval 
Methylnaltrexone (Relistor) Valeant Pharma 
International Inc 
opioid-induced constipation in patients with 
advanced illness receiving palliative care 
when response to laxatives has not been 
sufficient.  
opioid-induced constipation in patients with 
chronic noncancer pain who are treated 
with opioids.  
It is available as an injectable solution for 
subcutaneous use. 
Naloxegol (Movantik) AstraZeneca opioid-induced constipation in adults with 
chronic noncancer pain 
Naldemedine (Symproic) Shionogi opioid-induced constipation in adults with 
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Drug name (Brand name) Company Marketing approval 
noncancer pain. 
4.1.5 MARKET DRIVERS 
An increasing geriatric population and changing dietary habits in developed as well as developing 
markets is expected to increase the incidences of functional/idiopathic constipation. 
Although the prescription laxative market has historically been relatively flat, an increase in opioids 
consumption for relieving chronic pain is another factor driving the growth of the global constipation 
treatment market.  
The global constipation treatment market is hindered by the continuous reliance of a majority on 
over-the-counter (OTC) drugs, as well as on generic laxatives.  
 
4.2 THE MARKET FOR TREATING CONSTIPATION IN ANIMALS 
Chronic constipation is a highly debilitating condition that not only affects humans but also a 
number of animal species. Companion animals and horses are known to suffer from the condition 
and within species, prevalence is higher in certain breeds. The causes depend on the species and any 
underlying conditions that may be known to contribute to constipation: 
Species Causes 
Dogs 
prevalence of constipation is higher in: 
English Bulldogs 
Boston Terriers  
German Shepherds 
Old age and immobility 
Dehydration 
Obesity 
Systemic diseases e.g. neuromuscular disease, 
diabetic gastroparesis, neoplastic GI 
obstruction, anal sac inflammation 
Long term opioid use (e.g. tramadol)  
Chemotherapeutics (e.g. vincristine) 
Obstruction due to foreign object ingestion 
 
Cats 
Breeds/groups most affected include: 
Siamese  
Domestic Shorthair 
Manx  
Middle-aged and male cats 
Old age and immobility 
Dehydration 
Obesity 
Systemic diseases e.g. diabetes, bladder 
infection, anal sac infection, colitis or IBS 
Pain from trauma to the low back  
Hairball impaction 
Idiopathic 
 
Horses Dehydration 
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Impaction colics due to faecal material, 
parasites or sand 
Nutrition, e.g. impaction from poor food 
quality, inability to access free forage 
Stress 
Severe hind limb pain/injury 
Long term use of anticholinergic medications 
e.g. atropine 
Rabbits Digestive system resesmbles horses. Causes 
include: 
Dehydration 
Obesity 
Inactivity 
Spinal trauma 
Nutrition, e.g. low fibre diet, diet high in 
carbohydrates (i.e. fruit), diet high in protein 
(i.e. nuts) 
Hairballs 
Rodents 
(Guinea pigs and chinchillas) 
Old age 
Dehydration 
Obesity  
Lack of exercise 
Spinal pain 
Dental disease 
Nutrition, e.g. low fibre diet, diet high in 
carbohydrates (i.e. fruit), diet high in protein 
(i.e. nuts) 
Signs of constipation in pets and horses are summarized as: 
1. Increased straining 
2.  Failure to defecate 
3. Faecal matter, if passed, is reduced in quantity and is usually dry and hard 
4. Presence of blood in stool 
5. Faeces that are particularly foul smelling 
6. May continuously get in and out of litter box without passing fecal material 
7. Circling or pacing the stall with intermittent straining 
8. Decreased activity and lethargy likely due to pain 
9. Painful and/or bloated abdomen 
10. Decreased interest in food 
11. Irritability 
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As for humans, some drugs (eg, opioids, diuretics, antihistamines, anticholinergic agents, sucralfate, 
aluminum hydroxide, potassium bromide, and calcium channel-blocking agents) promote 
constipation via differing mechanisms.13 
Diagnosis requires collecting data to understand the history of how long the condition has been 
going on for, and discussing changes in the animal’s diet or daily toilet habits, performing physical 
examinations (abdominal and oral). Blood tests are routinely undertaken to rule in/out any other 
disease processes that may be contributing to the constipation. 
4.2.1 MARKET SIZE 
According to an industry trade group, the global market for animal medicines is about one-fortieth 
of that spent on human medicines14.  
We were not able to find any information on the prevalence of constipation in companion animals 
and horses. However, according to the American Pet Products Association, results from their 2017 
survey indicated 60% of households in the US own dogs (totaling 89.7million dogs), with 47% and 3% 
owning cats (94.2 million) and horse (7.6 million) respectively. Dog owners estimated they spent 
$257 in routine vet visits compared with $182 for cat owners, but these figures are likely to be lower 
than the real figure as they are based on recollection of spending only. 
4.2.2 TREATMENT 
As for humans, most treatments are focused on non-pharmacological approaches in the first 
instance, such as giving fluids for dehydration, increasing the amount of fiber in the animal’s diet and 
decreasing the amount of carbohydrates, or where there is foreign body obstruction, the surgical 
removal of the obstruction.  
Medication options available depend upon the species of animal and the exact type of gastric 
distress experienced. Pain control is usually considered as a treatment option in addition: 
Type Agent Species specific information 
Laxatives Paraffin oil 
Lactulose 
Risk of lung aspiration – best 
administered by vet 
Use with caution in diabetic animals. 
Not recommended for rabbits and 
rodents due to severe diarrheoa as a 
side effect 
Macrolide antibiotic Erythromycin Must not be given orally to rabbits, 
                                                          
13
 https://www.msdvetmanual.com/digestive-system/diseases-of-the-stomach-and-intestines-in-small-
animals/constipation-and-obstipation-in-small-animals 
14
 https://www.thebalance.com/of-the-largest-animal-pharmas-2663221 
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Type Agent Species specific information 
 
Azithromycin 
guinea pigs or other rodents 
 
H2 blockers Ranitidine (Zantac), Nizaditine  
5-HT4 serotonin 
receptor agonist/5-
HT3 receptor 
antagonist 
Cisapride (Propulsid) Used successfully in cats with IBS 
5-HT4 serotonin 
receptor agonist 
Prucalopride (Resolor)  
Dopamine antagonist Metoclopramide (Reglan) 
Domperidone 
Use limited due to CNS side effects 
Domperidone does not cross the 
blood brain barrier 
Cholinergic agonist Bethanechol Not recommended for use in rabbits 
or rodents 
Acetylcholinesterase 
inhibitor 
Neostigmine Not recommended for use in rabbits 
or rodents 
Type 2 chloride 
channel activator 
Lubiprostone (Amitiza) Pilot study in guinea pigs showed 
effectiveness in reversing opioid 
induced constipation. No studies 
conducted in cats, dogs or horses 
Guanylate cyclase C 
receptor peptide 
agonist 
Linaclotide (Linzess)  
Toxins Botulinum ? 
Continued or long-term use of laxatives is generally discouraged unless absolutely necessary. There 
is generally a lack of available products to treat chronic constipation and off-label use for drugs 
approved for humans are an option for vets, although compounding will be required to generate 
treatments at the correct dosage and formulation for the animal15. Chronic constipation that is 
unresponsive to medical management (e.g. some cats with megacolon) may be treated by surgical 
therapy (subtotal or total colectomy) which has associated risks and significant cost implications.16  
                                                          
15
 PetTalk (2012), volume 15(4): Constipation The Moving Truth about a Tough Topic in Pets! 
16
 https://www.msdvetmanual.com/digestive-system/diseases-of-the-stomach-and-intestines-in-small-
animals/constipation-and-obstipation-in-small-animals 
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4.2.3 MARKET DRIVERS 
As discussed above, the rise in pet ownership is driving a rise in the companion animal 
pharmaceutical product market, with total U.S. pet industry expenditures projected by the American 
Pet Products Association to rise by almost $3 billion to just over $69 billion in 2017. Today, 60 
percent of the revenue of U.S. animal health companies comes from companion animal products, 
and 40 percent comes from livestock products. In the rest of the world, these proportions are 
reversed. 
Pet owners are willing to spend more on their pets and are seeking products that will let their pets 
live longer, healthier lives. This market opportunity is driving new business models and is leading to 
the establishment of new companies focused on pet products. 
The development of a new animal drug can take up to 10 years and cost up to $100 million prior to 
approval by the FDA. In Europe, the costs are estimated at €150 million 
 
 
4.3 LEADING COMMERCIAL PLAYERS 
4.3.1 HUMAN HEALTH 
Leading companies in the constipation treatment market (based on sales17) include: 
Company  
 Marketed Pre- Phase III Phase II Preclinical Discovery 
                                                          
17
 Source: Global Data, data extracted 13 April 2018. Ordered highest-lowest annual revenue 
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Company  
Registration 
Sanofi 3      
Abbott 2      
Teva  3      
Takeda Pharmaceutical Co Ltd 2 1* 1*    
Allergan Plc 1     1 
Reckitt Benckiser Group Plc 1      
Astellas Pharma Inc 1* 1*   1  
Shire Pharmaceuticals 1* 1*     
Eisai 2      
Perrigo Company Plc 3      
Chugai Pharmaceutical Co Ltd 
(Subsidiary of Roche) 
1      
Sun Pharmaceutical Industries Ltd 2      
Sumitomo Dainippon Pharma Co    1   
Mallinckrodt  1* 1* 1*    
Aspen Pharmacare  3      
Ironwood Pharmaceuticals Inc  1*  2*   
EA Pharma Co Ltd 1 1 1     
Key:           
* same product 
 Laxatives or non-proprietary agents 
 Small molecule 
 Biologic 
Brief details of some of the key companies which are actively researching into constipation 
treatments identified by the secondary market research or the patent landscaping are given in 
Appendix 1. 
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4.3.2 ANIMAL HEALTH 
In the animal health industry, there are a very small number of Tier 1 players, and some smaller 
Tier 2 companies which are often more regionally based. We were not able to identify which of 
these companies leads the market in treatments for companion animal constipation. 
 
Tier 1 animal health companies (NB Boehringer-Ingelheim has now merged with Merial) 
 
Tier 2 animal health companies 
 
4.4 COMPETITIVE APPROACHES 
4.4.1 COMPETITORS 
Most healthcare organizations still consider standard laxatives as the first line of treatment for 
constipation as they are cheap and widely available. For example, a study comparing the costs of 
laxatives in Canada in 2014 revealed Lactulose cost CA$13/mo, while PEG 3350 CA$24/mo. In 
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contrast the prescription only medicines Lubiprostone, Linaclotide and Prucalopride cost from 
$80/mo to $240/mo18,19. 
4.4.2 PIPELINE 
A search was conducted on Global Data20 for therapeutics in active development for constipation 
(functional constipation; chronic idiopathic constipation; IBS-C). A number of drugs previously 
discussed in earlier sections either expanding their therapeutic indication or geographical marketing 
approval have been omitted for the sake of conciseness. Drugs acting on 5-HT4R predominate the 
pipeline of activity: 
Drug Name Company Name Indication MOA Development 
Stage 
Drug 
Geography 
AJG-555 EA Pharma Co Ltd Constipation laxative Pre-
Registration 
Japan 
BLI-400 Braintree 
Laboratories Inc 
Constipation laxative Phase III Global 
BLI-801 Braintree 
Laboratories Inc 
Constipation laxative Phase III Global 
SK-1202 Sanwa Kagaku 
Kenkyusho Co Ltd 
Constipation undisclosed Phase III Japan 
tenapanor Ardelyx Inc Constipation; Irritable Bowel 
Syndrome 
NHE3 inhibitor Phase III United 
States 
DSP-6952 Sumitomo 
Dainippon 
Pharma Co Ltd 
Constipation; Irritable Bowel 
Syndrome 
serotonin-4 
receptor partial 
agonist 
Phase II Japan 
ENT-01 Enterin Inc Constipation alpha synuclein Phase II United 
States 
lovastatin MR Synthetic 
Biologics Inc 
Constipation; Irritable Bowel 
Syndrome 
gut microbes 
(methanogens) 
Phase II United 
States 
naronapride Renexxion LLC Constipation; Functional (Non 
Ulcer) Dyspepsia; Reflux 
Esophagitis (Gastroesophageal 
Reflux Disease) 
5HT4 agonist Phase II Global 
NGM-282 NGM Biopharma 
Inc 
Constipation; Non-Alcoholic 
Steatohepatitis (NASH) 
FGFR4 and FGFR1 
agonist 
Phase II Global 
                                                          
18
 Kosar L, Schuster B. RxFiles drug comparison charts. 10th ed. Saskatoon, SK: RxFiles; 2014. Constipation and 
laxatives. 
19
 Clin Interv Aging. 2010; 5: 163–171 
20
 Data extracted 13 April 2018 
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Drug Name Company Name Indication MOA Development 
Stage 
Drug 
Geography 
relenopride 
hydrochloride 
SK Biopharma Co 
Ltd 
Constipation; Irritable Bowel 
Syndrome 
5-HT4 receptor 
partial agonist 
Phase II South 
Korea; 
United 
States 
YH-12852 Yuhan Corp Constipation; Postoperative  
Ileus 
5-HT4 receptor 
agonist 
Phase II Global 
DA-6886 Dong-A ST Co Ltd Constipation; Irritable Bowel 
Syndrome 
5-HT4 agonist Phase I South 
Korea 
RQ-00000010 RaQualia Pharma 
Inc 
Constipation; Functional (Non 
Ulcer) Dyspepsia; Gastroparesis 
5-HT4 receptor 
partial agonist 
Phase I United 
Kingdom 
ASP-7663 Astellas Pharma 
Inc 
Constipation (drug induced) TRPA1 agonist Preclinical Global 
J-027 Vanda 
Pharmaceuticals 
Inc 
Constipation cystic fibrosis 
transmembrane 
conductance 
regulator (CFTR) 
Preclinical Global 
ZS-06 Zensun (Shanghai) 
Sci & Tech Co Ltd 
Constipation laxative Preclinical Global 
Biologic for 
Irritable Bowel 
Syndrome with 
Constipation 
Allergan Plc Constipation; Irritable Bowel 
Syndrome 
Undisclosed 
(microbiome?) 
Discovery Global 
5-BIOP Technical 
University of 
Munich 
Constipation; Functional (Non 
Ulcer) Dyspepsia 
putative 5-HT (1P) 
receptor agonist 
Discovery Global 
4.4.3 COMPETITIVE POSITION 
TNF-ALPHA ANTAGONISTS FOR THE TREATMENT OF CONSTIPATION 
TNF-alpha inhibitors are a class of biological medicines authorised for the treatment of inflammatory 
and autoimmune conditions, such as rheumatoid arthritis, ankylosing spondylitits, Crohn’s disease, 
ulcerative colitis, psoriasis, and psoriatic arthritis. The TNF-alpha inhibitors authorised in the UK are 
adalimumab, certolizumab, etanercept, golimumab, and infliximab. TNF-alpha inhibition increases 
susceptibility to infectious diseases, including tuberculosis) and increases the risk of reactivation of 
latent tuberculosis). All approved antagonists interact with a variety of vaccines that increase the 
risk of generalised infection that could possibly be life-threatening, including the influenza vaccine. 
With the exception of Etanercept, all drugs are contraindicated in individuals with moderate or 
severe heart failure, and all drugs are contraindicated in individuals with either active or severe 
infections21.  
                                                          
21
 MHRA Drug Safety Update: TNF-alpha inhibitors 
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Biologic pharmaceuticals are generally known to be more expensive than chemically synthesized 
agents. In the UK, Etanercept costs the NHS anywhere between £328 - £715 per month, depending 
on the distributor and the type of injection delivery system22. 
A search conducted on Global Data23 returned zero results for drugs targeting TNF-alpha for the 
treatment of constipation. 
4.4.4 REGULATORY ISSUES 
We have not looked in detail at the regulatory route for a novel TNF-alpha antagonist for an 
indication of constipation. However, key issues in allowing uptake of such a drug will surround 
reimbursement status and an assessment of cost-benefit. Any new drug for the treatment of 
constipation will need to differentiate itself from its competitors, which include very low cost 
laxatives as well as prescription medicines. 
Safety is also an important issue when it comes to treatment of the elderly population, who will 
often have other co-morbidities. The potential side-effects from TNF-alpha antagonists may be 
acceptable in a serious chronic disease such as rheumatoid arthritis, but the regulatory barriers 
would be higher for a condition such as constipation. If there is a market for the healthy elderly, it 
would be important to show that any new drug with this mode of action does not have unwanted 
effect on the heart or the kidney. Similarly, the route of administration via needle infusion may be 
acceptable for severely affected patients, but is unlikely to be preferred until other less invasive 
options have been exhausted. It would certainly not be possible to position this type of drug as an 
over the counter or home administration product without reformulation. 
 
Given the availability of low-cost, very safe, and relatively efficacious OTC alternatives, a high-cost, 
injectable medicine with the potential for severe side effects and which causes a reduction in 
immune competence would rank very low down the list of treatment options for what is a 
distressing, but not life-threatening condition. We would therefore expect the market share for a 
treatment of this nature to be a very small segment of the overall market. 
                                                          
22
 For 4 x 50mg per 1ml 
23
 Search conducted 12 April 2018 
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5 INTELLECTUAL PROPERTY LANDSCAPE AND OPPORTUNITIES 
The initial research establishing the potential link between anti-TNF-α drugs and relief of 
constipation has been published by the team, but no IP protection has yet been put in place. 
However, the opportunity for IP protection for this work may arise from further translational 
research to identify and develop treatments which combine TNF-α antagonism with targeted 
delivery mechanisms, allowing them to act directly on the colon. This may be through re-formulation 
of existing biologics, or the identification of novel compounds. 
5.1 BROAD PATENT SEARCH 
In order to understand the scope of third party patents relating to anti-TNF drugs in constipation, 
IP Pragmatics used their subscription patent landscape tool, Derwent Innovation. This is a 
comprehensive patent database and patent landscaping tool that can quickly identify competing or 
synergistic patents and their assignees as part of an overall IP analysis. This tool can also help 
identify potential licensees and co-development partners. The initial search was focused on 
identifying the general trends regarding patents surrounding treatment of chronic constipation in 
the elderly. 
The following document collections were searched: 
Full Text: US Granted; US Applications; European Granted; European Applications; WIPO 
Applications; Australian Innovation; Australian Granted; Australian Applications; British Granted; 
British Applications; French Applications; French Granted; German Granted; German Utility Models; 
German Applications; Canadian Granted; Canadian Applications; Russian Utility Models; Russian 
Applications 
Bibliographic: Japanese Applications; Korean Granted/Examined; Korean Applications; Other 
Authorities (covered by INPADOC); plus enhanced Derwent World Patent Index (DWPI) data fields 
A broad general search was used to illustrate the level of activity in the field. In order to restrict the 
search set to patents which may still be in force, the search was limited to the last 20 years: 
(CTB=(constipat*) OR IC=(A61P000110)) AND CTB=(elderly or old or older or age or ageing or aging) 
AND CTB=(chronic) AND DP>=(19980101); 
o This searched the claims, title and abstracts of patents published from 1998 and identified 
5,010 individual patent cases in 464 INPADOC patent families. 
The IC term used in the search is for the International Patent Classification (IPC) code. The IPC codes 
provide a hierarchical system of language independent symbols for the classification of patents and 
utility models according to the different areas of technology to which they pertain. The IPC divides 
technology into eight sections with approximately 70,000 subdivisions. The appropriate IPC symbols 
are indicated on each patent document, of which more than 1,000,000 were issued each year in the 
last 10 years. The IPC code in this search relates to drugs for gastro-intestinal disorders, specifically 
laxatives. 
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5.1.1 GENERAL TRENDS 
The patents identified in this broad search were analysed to identify some overall trends and 
features of this patent space. The following graph shows the new patent family publishing trends in 
this field by year: 
 
It can be seen that there was a steady rise in activity during the 2000s, but since then there has been 
a slight decline in new patenting activity. The data for 2018 are not yet complete, hence the sharp 
drop in activity at the end of the chart. There are approximately 80 new patent families published 
each year for this topic, which is a fairly low number compared with many other therapeutic 
indications. 
A similar trend can be seen from a search of the academic literature, carried out in Scopus. After 
1999, the number of publications relating to chronic constipation has increased steadily year on 
year. In most recent years, approximately 700 articles or reviews are published each year:  
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Source: Scopus 
Of the 10,067 publications over this period, the majority fall within the category of medicine. 
Veterinary publications make up only 46 documents (0.5%): 
 
Source: Scopus 
 
The broad patent search was then analysed by top priority countries, to see where the patent 
applications are initially being filed. This can be a good indication of the countries where the 
majority of the research and innovation in a particular technology field is taking place since 
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organisations generally file patent applications first in the local territory where their research bases 
are located. 
 
In this case, the majority of patenting activity comes from the US, with more than half of the overall 
patenting activity. This reflects the US being the home to several of the major pharmaceutical 
companies. From the remaining territories, Asia is also strong through Japan and China, as well as 
Europe (including France, Denmark, GB, Denmark, Austria and Israel). 
The countries in which assignees have chosen to protect inventions in a particular sector can be used 
as an indication of the territories these organisations consider are commercially important to protect 
for their products. This is shown in the chart below: 
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This analysis identifies the major markets for sale and/or manufacture of these products, which can 
be seen to be worldwide. The top 5 markets include the U.S., Europe, Japan and Australia, while 
direct PCT filing is also important. Other strong territories are Canada, South Korea, China, Russia, 
and Israel. 
5.1.2 TOP ASSIGNEES 
The top assignees in this search are shown in the table below. Individual inventors and unspecified 
assignees have been removed from this list for clarity. Document count refers to the number of 
patent families (rather than individual patents). The table includes some of the major 
pharmaceutical companies: 
DWPI Assignee/Applicant  Document Count  Percentage  
TARGACEPT INC/TRGA 45 6.09% 
CATALYST BIOSCIENCES INC/CATA-N 17 2.30% 
BRISTOL-MYERS SQUIBB CO/BRIM 16 2.17% 
FOAMIX LTD/FOAM-N 14 1.89% 
FOAMIX PHARM LTD/FOAM-N 14 1.89% 
GLAXO GROUP LTD/GLAX 14 1.89% 
AVENTIS PHARM AS/AVET 14 1.89% 
AVENTIS PHARMA SA/AVET 14 1.89% 
NEUROSEARCH AS/NURO 13 1.76% 
SALIX PHARM INC/SALI-N 11 1.49% 
TRANZYME PHARMA INC/TRAN-N 10 1.35% 
TAKEDA PHARM CO LTD/TAKE 10 1.35% 
HELSINN HEALTHCARE SA/HELS-N 9 1.22% 
TAKEDA CHEM IND LTD/TAKE 9 1.22% 
TAKEDA PHARM IND CO LTD/TAKE 9 1.22% 
TAKEDA PHARM/TAKE 9 1.22% 
ICAGEN INC/ICAG 9 1.22% 
VERTEX PHARM INC/VERT 8 1.08% 
NUTRICIA NV/DNON 7 0.95% 
SOC CONSEILS RECH & APPL SCI/SCRC 7 0.95% 
SALIX PHARM LTD/SALI-N 7 0.95% 
Confidential 
 
t:   +44 (0) 203 176 0580 | +44 (0)131 221 6570 
w:  http://www.ip-pragmatics.com 32 | P a g e  
a:  47 Mount Pleasant, London, WC1X 0AE, UK | Forth House, 28 Rutland Square, Edinburgh, EH1 2BW, UK 
DWPI Assignee/Applicant  Document Count  Percentage  
OCERA THERAPEUTICS INC/OCER-N 6 0.81% 
CHIASMA/CHIA-N 6 0.81% 
CHIASMA INC/CHIA-N 6 0.81% 
CHIASMA LTD/CHIA-N 6 0.81% 
The most prolific company, Targacept was taken over by the second, Catalyst Biosciences in 2015. 
Targacept had a drug development program in constipation-predominant IBS, but this is no longer a 
focus for Catalyst Biosciences. 
By plotting the top assignees against patent publication year, the most prolific organisations 
patenting in this field in recent years can be identified, as illustrated in the figure below. 
 
 
5.2 PATENT LANDSCAPING 
Derwent Innovation can be used to generate sophisticated patent landscapes to visualise the 
relationship between patents in a common field based on key words within the claims and/or 
abstracts/text of individual patents within the searched field. This can be used to locate competing 
or similar patents to the patents of interest. As with a geographic landscape the contour lines and 
intensity of peaks on the patent landscape represent areas of high patent activity with closely 
related concepts.  
The patent set was mapped using Derwent Innovation’s proprietary ThemeScape™ mapping tool. 
ThemeScape uses term frequency and other algorithms to cluster documents based on shared 
language – in this case the English Title, Abstracts and Claims from the patents together with the 
DWPI-enhanced Titles and Abstracts were mapped. It uses several algorithms to perform 
terminology-based clustering. The text from one record is compared with the text from all other 
patent records within the search collection. The map uses vectors to give each patent record a 
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proximity score to all of its peers. The outcome of this analysis is a visualisation of the patent space 
with each patent (dot) represented once in the map, with patents in close proximity sharing more 
phraseology than those located apart. Each peak is labelled with the key terminology concepts 
contained in the patents within the cluster. 
The resulting maps are shown below. The first chart shows the overall landscape. The second chart 
shows the patents within this landscape which refer to etanercept within their title, abstract or 
claims. This highlights a small group of related patent families, but on further inspection these do 
not relate to the use of etanercept for constipation. The third chart shows more generally which 
patents are concerned with TNF or anti-inflammatories. These can be seen to be spread across the 
whole landscape, and not concentrated into any particular region. 
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Red dots show patents relating to etanercept 
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Green dots show patents relating to anti-inflammatories 
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5.3 FOCUSED SEARCH FOR ANTI-TNF DRUGS IN CONSTIPATION 
A more focused search was carried out to identify if any patents concern the link identified by the 
team of anti-TNF drugs, specifically etanercept, in the treatment of constipation. The search was 
complicated by the fact that anti-TNF drugs are commonly prescribed for ulcerative colitis, which has 
constipation as one of its symptoms. 
(CTB=((tnf or tnfalpha or tnfa or antitnf or (tumour adj necrosis) or (tumor adj necrosis) or enbrel or 
etanercept or etacept or benepali or erelzi)) OR IC=((C07K0014525))) AND CTB=(constipat*) AND 
DP>=(19980101); 
The IPC code used in this search is for tumour necrosis factor (TNF). 
o This searched the claims, title and abstracts of patents published from 1998 and identified 
2,668 individual patent cases in 193 INPADOC patent families. 
The top assignees in this search are shown in the table below. Individual inventors and unspecified 
assignees have been removed from this list for clarity. Document count refers to the number of 
patent families (rather than individual patents). 
DWPI Assignee/Applicant  Document Count  Percentage  
NESTEC SA/NEST 18 3.90% 
PROMETHEUS LAB INC/PROM-N 17 3.68% 
PROGENICS PHARM INC/PRGN 15 3.25% 
BIOSUCCESS BIOTECH CO LTD/BIOS-N 10 2.16% 
MAPIKS EHS EHJ AR EHL/MAPI-N 10 2.16% 
GLENMARK PHARM INC U/GLMK 9 1.95% 
GLENMARK PHARM SA/GLMK 9 1.95% 
STEALTH BIOTHERAPEUTICS CORP/STEA-N 9 1.95% 
UNIV SOUTHERN CALIFORNIA/USCA 6 1.30% 
EPEIUS BIOTECHNOLOGIES CORP/EPEI-N 6 1.30% 
STEALTH PEPTIDES INT INC/STEA-N 6 1.30% 
CELGENE CORP/CGEN 5 1.08% 
GLAXOSMITHKLINE/GLAX 5 1.08% 
BIOSEARCH SA/BIOS-N 5 1.08% 
PULEVA BIOTECH SA/PULE-N 5 1.08% 
DAVIDSON LOPEZ LLC/DAVI-N 5 1.08% 
LOPEZ LLC DAVIDSON/LOPE-N 5 1.08% 
ADVINUS THERAPEUTICS LTD/ADVI-N 4 0.87% 
SYNERGY PHARM INC/SYNE-N 4 0.87% 
GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGR/GLAX 4 0.87% 
GLAXOSMITHKLINE ISTRAZIVACKI CENT ZAGREB/GLAX 4 0.87% 
PLIVA ISTRAZIVACKI INST DOO/PLIV 4 0.87% 
DA VOLTERRA/VOLT-N 4 0.87% 
 
The patent families identified by this search were scanned manually for relevance. No patents which 
disclose the use of anti-TNF drugs specifically for constipation were identified, but as mentioned 
above, constipation is one of the symptoms which may be indicative of a therapeutic indication for 
this class of drug. The most relevant patents from this search are shown in the table below: 
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Note: To access the full text of these patents, please click on the hyperlinked publication number to 
retrieve a summary of the patent. A pdf of the original file can then be downloaded by clicking the 
pdf logo located just to the left of the words “Full View” at the top left of the screen. 
Publication Number Title (English) Assignee/Applicant Priority 
Date 
Publication 
Date 
WO2015051337A2 METHODS OF TREATING 
GASTROINTESTINAL 
DISORDERS 
EMORY UNIVERSITY,US 2013-10-04 2015-04-09 
Method (M1) of improving enteric nerve cell survival in patient in need exhibiting symptoms of colitis, involves 
administering TNF-α inhibitor to the patient, that reduces neuropeptide-Y (NPY). 
The method (M1) is useful for improving enteric nerve cell survival in patient in need exhibiting symptoms of 
colitis. The method (M2) is useful for decreasing tight junction permeability. The method (M3) is useful for 
diagnosing disorder associated with gastrointestinal motility. The TNF-α inhibitor is useful for improving 
colonic cell motility, and improving symptoms associated with irritable bowel syndrome, chosen from 
dyspepsia, bloating, abdominal pain, diarrhea and constipation (all claimed). 
AU2014235209A1 Guanylate cyclase 
receptor agonists 
combined with other 
drugs 
Synergy Pharmaceuticals Inc. 2013-03-15 
| 2013-05-
23 | 2014-
03-13 
2015-10-01 
Composition comprises a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of sequence 
as given in the tables 1-8 of the specification and a compound including 5-aminosalicyclic acid or its derivative 
or salt, mercaptopurine, an anti-TNF therapy or an antibiotic. 
The composition is useful for: preventing or treating a condition including ulcerative colitis, Crohn's disease, 
irritable bowel syndrome, non-ulcer dyspepsia, chronic intestinal pseudo-obstruction, functional dyspepsia, 
colonic pseudo-obstruction, duodenogastric reflux, constipation, constipation associated with use of opiate 
pain killers, post-surgical constipation, constipation associated with neuropathic disorders, gastroesophageal 
reflux disease, Celiac disease, gastroparesis, heartburn, poor gastrointestinal motility, congestive heart failure, 
hypertension, benign prostatic hyperplasia, colon cancer, lung cancer, bladder cancer, liver cancer, salivary 
gland cancer or skin cancer, bronchitis, tissue inflammation, organ inflammation, respiratory inflammation, 
asthma, chronic obstructive pulmonary disease, lipid metabolism disorders, biliary disorders, cardiovascular 
disease, obesity and an endocrine disorder in a subject; colonic cleansing in a subject (all claimed); treating 
gastrointestinal disorders e.g. irritable bowel syndrome, inflammatory bowel disease and excessive acidity, 
cardiac disorders including eye disorders, oral disorders, blood disorders, liver disorders, skin disorders and 
prostate disorders, where the lipid metabolism disorders include e.g. dyslipidemia, hyperlipidemia and 
hypercholesterolemia, and the biliary disorders include gallbladder disorders and lung disorders. No biological 
data given. 
AU2012211459A1 (R)-N-methylnaltrexone, 
processes for its 
synthesis and its 
pharmaceutical use 
Progenics Pharmaceuticals 
Inc. 
2006-05-25 2012-08-30 
A composition comprises (R)-N-methylnaltrexone (R-MNTX). The composition is free of high performance 
liquid chromatography (HPLC) detectable S-MNTX at a detection limit of 0.02%, and at a quantitation limit of 
0.05%. 
For treating or preventing opioid-induced side effects (e.g. constipation, immune suppression, inhibition of 
gastrointestinal motility, inhibition of gastric emptying, nausea, emesis, incomplete evacuation, bloating, 
abdominal distension, increased gastroesophageal reflux, hypotension, bradycardia, gastrointestinal 
dysfunction, pruritus, dysphoria, and urinary retention); to promote gastrointestinal motility, gastric emptying 
or relief of constipation where a patient is receiving an opioid for pain resulting from surgery; for treating or 
preventing endogenous opioid-induced gastrointestinal dysfunction (e.g. inhibition of gastrointestinal motility, 
constipation and postoperative bowel dysfunction); for preventing or treating idiopathic constipation; for 
treating irritable bowel syndrome; for inducing laxation; and for preventing or treating post-operative bowel 
dysfunction (e.g. delayed gastric emptying or inhibition of gastrointestinal motility) (claimed). 
IT1407225B Composition used for 
treating 
MAPIKS EHS EHJ AR EHL | 
EHPSHTEYN O I | EPSHTEIN O 
 2014-03-28 
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Publication Number Title (English) Assignee/Applicant Priority 
Date 
Publication 
Date 
disease/condition of 
functional etiology of 
gastrointestinal tract 
comprises activated-
potentiated form of 
antibody to histamine, 
antibody to tumor 
necrosis factor-alpha and 
antibody to brain specific 
protein 
I | EPSHTEIN O L | EPSHTEIN 
O | EPSTEIN O I | ILIICH E O 
A combination pharmaceutical composition (C1) comprises a) an activated-potentiated form of an antibody to 
S-100 protein, b) an activated-potentiated form of an antibody to histamine, and c) an activated-potentiated 
form of an antibody to tumor necrosis factor-alpha (TNF-α ).  
For treating disease or condition of functional etiology of the gastrointestinal tract, where the disease or 
condition is psychosomatic in nature, irritable bowel syndrome, abdominal pain, diarrhea, constipation, or is a 
distortion in the motor-evacuatory function of the gastrointestinal tract (where the irritable bowel syndrome is 
predominantly by abdominal pain and flatule, diarrhea, or by constipation) (claimed). 
AU2014331812A1 Agonists of guanylate 
cyclase useful for 
downregulation of pro-
inflammatory cytokines 
Synergy Pharmaceuticals Inc. 2013-10-09 
| 2014-10-
09 
2016-04-28 
A composition comprises a guanylate cyclase receptor agonist (GCRA) peptide comprising of the sequence of 
any one of Tables 1-7, given in the specification, and a Nuclear Factor (NF)-kappaB inhibitor, a c-Src tyrosine 
kinase inhibitor, a 5-aminosalicylic acid (5-ASA) agent, a c-Myc inhibitor, or an IkappaB kinase (Ikk) inhibitor. 
The composition is used for preventing or treating a condition selected from colitis, ulcerative colitis, Crohn's 
disease, irritable bowel syndrome (IBS), non-ulcer dyspepsia, chronic intestinal pseudo-obstruction, functional 
dyspepsia, colonic pseudo-obstruction, duodenogastric reflux, constipation, constipation associated with use 
of opiate pain killers, post-surgical constipation, IBS-associated constipation, constipation associated with 
neuropathic disorders, gastroesophageal reflux disease (GERD), Celiac disease, gastroparesis, heartburn, poor 
gastrointestinal motility, congestive heart failure, hypertension, benign prostatic hyperplasia (BPH), 
gastrointestinal cancer, lung cancer, bladder cancer, liver cancer, salivary gland cancer, skin cancer, bronchitis, 
tissue inflammation, organ inflammation, respiratory inflammation, asthma, chronic obstructive pulmonary 
disease (COPD), lipid metabolism disorder, biliary disorder, cardiovascular disease, obesity and an endocrine 
disorder; treating or alleviating a symptom of a NF-kappaB mediated inflammation; modulating NF-kappaB 
induction in a cell; and modulating NF-kappaB-dependent target gene expression in a cell (all claimed). 
JP2005200316A FEED, FEED ADDITIVE 
AND CHEMICAL FOR 
ANIMAL COMPRISING 
PULVERIZED MATERIAL 
AND/OR EXTRACTED 
MATERIAL OF LOTUS 
TOOYOO GIJUTSU 
KENKYUSHO KK | NIPPON 
ALLERGIE OYO KENKYUSHO 
KK 
2004-01-13 2005-07-28 
Feed for animals, containing crushed material and/or extract of a lotus, is new. 
The feed is useful for treating allergic disease such as pollinosis, bronchial asthma and atopic dermatitis, and 
constipation in animals such as dog, cat, horse, pig, cow, goat, sheep, etc. 
AU2006211996A1 Colonic delivery of active 
agents 
Centre National de la 
Recherche Scientifique,FR | 
Da Volterra,FR 
2005-02-09 
| 2006-02-
09 
2007-08-16 
An oral drug delivery device comprises active agent capable of inactivating antibiotic, and drug delivery device 
comprising pectin beads, where pectin is crosslinked with calcium ions, and reticulated with 
polyethyleneimine.  
For delivering active agents such as aminosalicylate, drugs containing 5-aminosalicylic acid (5-ASA), 
corticosteroids, immunomodulators, cyclosporine A, TNF α, thiazolidinedione and glitazones for treating 
Crohn's disease and ulcerative colitis, for delivering active agent selected from anti-proliferative agents, agents 
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Publication Number Title (English) Assignee/Applicant Priority 
Date 
Publication 
Date 
for DNA modification or repair, DNA synthesis inhibitors, DNA/RNA transcription regulators, enzyme 
activators, enzyme inhibitors, gene regulators, HSP-90 inhibitors, microtubule inhibitors, agents for 
phototherapy and therapy adjuncts for treating colon cancer, delivering active agent selected from stimulant 
laxatives, osmotic laxatives, stool softeners, bulking agents and anticholinergic medications for treating 
irritable bowel syndrome or constipation. Also used as diagnostic agent when encapsulated agent is diagnostic 
agent selected from radiolabeled compounds, radiopaque compounds and gases, for diagnosing disorder in 
colon (all claimed). 
HK1228777A0 Composition used for 
preventing or treating a 
condition, e.g. ulcerative 
colitis, heartburn, 
hypertension, cancer, 
and obesity, comprises a 
guanylate cyclase 
receptor agonist peptide 
SYNERGY PHARM INC  2017-11-10 
A composition comprises a guanylate cyclase receptor agonist (GCRA) peptide comprising of the sequence of 
any one of Tables 1-7, given in the specification, and a Nuclear Factor (NF)-kappaB inhibitor, a c-Src tyrosine 
kinase inhibitor, a 5-aminosalicylic acid (5-ASA) agent, a c-Myc inhibitor, or an IkappaB kinase (Ikk) inhibitor.  
The composition is used for preventing or treating a condition selected from colitis, ulcerative colitis, Crohn's 
disease, irritable bowel syndrome (IBS), non-ulcer dyspepsia, chronic intestinal pseudo-obstruction, functional 
dyspepsia, colonic pseudo-obstruction, duodenogastric reflux, constipation, constipation associated with use 
of opiate pain killers, post-surgical constipation, IBS-associated constipation, constipation associated with 
neuropathic disorders, gastroesophageal reflux disease (GERD), Celiac disease, gastroparesis, heartburn, poor 
gastrointestinal motility, congestive heart failure, hypertension, benign prostatic hyperplasia (BPH), 
gastrointestinal cancer, lung cancer, bladder cancer, liver cancer, salivary gland cancer, skin cancer, bronchitis, 
tissue inflammation, organ inflammation, respiratory inflammation, asthma, chronic obstructive pulmonary 
disease (COPD), lipid metabolism disorder, biliary disorder, cardiovascular disease, obesity and an endocrine 
disorder; treating or alleviating a symptom of a NF-kappaB mediated inflammation; modulating NF-kappaB 
induction in a cell; and modulating NF-kappaB-dependent target gene expression in a cell (all claimed). 
US20160287525A1 COMPOSITIONS FOR 
COLONIC DELIVERY OF 
DRUGS 
BANNER LIFE SCIENCES LLC | 
BANNER LIFE SCIENCES 
LLC,High Point,NC,US 
2015-04-06 2016-10-06 
An oral pharmaceutical composition comprises controlled-release matrix encapsulated in soft capsule shell. 
The controlled-release matrix comprises lipid(s) or lipophilic vehicle(s), hydrophilic polymer(s), hygroscopic 
polymer(s), nonionic surfactant(s), and active pharmaceutical ingredient(s). The matrix dissolves in the colon.  
Pharmaceutical composition in the form of soft capsule or enteric soft capsule, used for treating, preventing, 
ameliorating, retarding progression, delaying onset, or reducing symptoms of bowel disease including 
inflammatory bowel disease, irritable bowel syndrome, colon cancer, or colorectal cancer (claimed). 
IN200904408P1 Delayed release oral 
solid dosage form, useful 
to treat e.g. ulcerative 
colitis, comprises a core 
comprising a drug and a 
diluent; and a delayed 
release material 
comprising one or more 
natural or synthetic 
gums 
PENWEST 
PHARMACEUTICALS CO. 
2003-09-19 2012-04-27 
Delayed release oral solid dosage form (A) comprises a core (I) comprising a drug, which can be absorbed in 
the colon and a diluent; and a delayed release material (II) compression coated onto the surface of (I), (II) 
comprising one or more natural or synthetic gums.  
(A) is useful to treat Crohn's disease and/or ulcerative colitis in humans (claimed). (A) is useful to treat colon 
cancer. 
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An alternative focused search strategy was then used, to focus on the wider topic of chronic 
constipation and gastro-intestinal diseases in the elderly, combined with anti-TNF drugs: 
(CTB=((tnf or tnfalpha or tnfa or antitnf or (tumour adj necrosis) or (tumor adj necrosis) or enbrel or 
etanercept or etacept or benepali or erelzi)) OR IC=((C07K0014525))) AND (CTB=(constipat*) OR 
IC=(A61P000110)) AND CTB=(elderly or old or older or age or ageing or aging) AND CTB=(chronic) 
AND DP>=(19980101); 
o This searched the claims, title and abstracts of patents published from 1998 and identified 
290 individual patent cases in 24 INPADOC patent families. 
The top assignees in this search are shown in the table below. Individual inventors and unspecified 
assignees have been removed from this list for clarity. In this case, the document count refers to the 
number of individual patents (rather than patent families). 
DWPI Assignee/Applicant  Document Count  Percentage  
BIOSUCCESS BIOTECH CO LTD/BIOS-N 96 9.45% 
CARA THERAPEUTICS INC/CARA-N 74 7.28% 
BIOSUCCESS BIOTECH CO/BIOS-N 45 4.43% 
BIOSUCCESS BIOTECH LTD/BIOS-N 45 4.43% 
ABBOTT GMBH&CO KG/ABBO 25 2.46% 
ABBOTT LAB/ABBO 25 2.46% 
ABBVIE INC/ABBI 25 2.46% 
PHARMACIA CORP/PHAA 23 2.26% 
UNIV CALIFORNIA/REGC 4 0.39% 
STEALTH BIOTHERAPEUTICS CORP/STEA-N 2 0.20% 
STEALTH PEPTIDES INT INC/STEA-N 2 0.20% 
CERA THERAPEUTICS INC/CERA-N 2 0.20% 
TAIYO KAGAKU KK/TAIC 1 0.10% 
CLEVELAND BIOLABS INC/CLEV-N 1 0.10% 
The full set of results for this search is provided in the attached file: chronic constipation in elderly 
and TNF families.xls. These results were scanned manually for relevance, but do not appear to be 
directly relevant to the Brighton approach. 
 
5.4 THE UNIVERSITY INTELLECTUAL PROPERTY POSITION 
Important Note: This analysis is not intended as a legal opinion on freedom to operate or 
patentability. Instead it aims to identify the complexity of the patent landscape from a commercial 
perspective in order to identify competing approaches and third party patents that need to be 
considered; and to identify partners with similar IP that may be combined with the organisation’s IP. 
An examination of the patent landscape suggests that there is a fairly low interest in patents which 
address the treatment of chronic constipation in the elderly. The searches carried out have not 
identified any patents which relate to treatment of constipation directly with anti-TNF-α drugs. 
However, as constipation is a side-effect of conditions such as ulcerative colitis which is treated with 
anti-TNF-α drugs, this additional use of this class of drugs may have been considered obvious. The 
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opportunity to patent the link between anti-TNF-α drugs and relief of constipation has anyway now 
passed as the research has been published by the team.  
The patent literature suggests that investigation of treatments which combine TNF-α antagonism 
with targeted delivery mechanisms, allowing them to act directly on the colon is not an active area 
of interest, either in the pharmaceutical companies or amongst academics. We did identify some 
patents relating to re-formulation approaches to allow biologics to reach the colon, although no 
specific searching was done for this particular aspect. Where novel compounds with anti-TNF-α 
activity were being developed, this was for other indications. 
There may therefore be an opportunity to develop an intellectual property position around novel 
compounds or novel delivery mechanisms targeting anti-TNF-α drugs for constipation. 
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6 INDUSTRY FEEDBACK 
6.1 STAKEHOLDER APPROACHES 
In order to further substantiate the findings from the secondary market research and identify 
potential partners, contacts have been made with a range of relevant healthcare professionals and 
companies with an interest in constipation and/or TNF-α antagonists for both human and animal 
health. The aim was to obtain feedback regarding the attractiveness of this new approach and to 
understand where it sits in the overall commercial landscape. Where possible, IP Pragmatics has 
followed up with the companies in direct meetings over the phone to try to gain additional insights. 
However in this case, we have only received limited direct feedback, with many of the responses 
coming via email and declining a conversation. 
Suitable targets were selected from a combination of the market research and IPP knowledge of this 
industry. The companies contacted are shown in the table below. We also contacted a selection of 
healthcare experts in the human and veterinary field. 
Company Reason for interest Comments 
Janssen Inc Pharma companies: with TNFalpha 
products; 
Pharma companies: constipation 
therapy area 
 
Medimmune Pharma companies: with TNFalpha 
products 
Originator of Abbott's Humira 
Merck & Co Inc Pharma companies: with TNFalpha 
products 
  
Pfizer Inc Pharma companies: with TNFalpha 
products 
Originator of Etanercept: market interest for sc 
injection + biological product for constipation? 
Sandoz Inc Pharma companies: with TNFalpha 
products 
Have a biosimilar for etanercept 
Abbott Pharma companies: constipation 
therapy area 
Sells lactulose (Duphalac) 
Eisai Pharma companies: constipation 
therapy area 
Laxatives 
Novartis Pharma companies: constipation 
therapy area 
Developed Tegaserod (withdrawn from US 
market) 
Sanofi Pharma companies: constipation 
therapy area 
Sodium picosulfate laxative POM 
Takeda Pharma companies: constipation 
therapy area 
Laxative and targeted therapy (not their own) 
Also sell Enbrel in Japan 
Bristol-Myers 
Squibb Co 
Pharma companies: ulcerative 
colitis therapy area 
 
Celgene Corp Pharma companies: ulcerative 
colitis therapy area 
 
Eli Lilly and Co Pharma companies: ulcerative 
colitis therapy area 
 
GlaxoSmithKline Plc Pharma companies: ulcerative 
colitis therapy area 
 
Johnson & Johnson Pharma companies: ulcerative 
colitis therapy area 
 
Johnson & Johnson 
Inc 
Consumer health companies, esp 
those with gut health products 
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Company Reason for interest Comments 
Bayer AG Consumer health companies, esp 
those with gut health products 
 
Bayer Healthcare 
Animal Health 
Animal health companies manufactures antimicrobials, parasiticides, 
sedatives, pain killers, and nutritional 
supplements and feed additives for dogs, cats 
and horses. Products for food animals include 
antiinfectives, vaccines, parasiticides and 
sedatives and pain killers 
Boehringer 
Ingelheim (merged 
with Merial) 
Animal health companies markets biologicals, vaccines, pharmaceuticals 
and other care products for use in pets and 
livestock 
Elanco (merged with 
Novartis Animal 
Health) 
Animal health companies develops and markets products to treat animal 
health and increase protein production. 
Products include flea protection for dogs and 
cats, drugs to combat parasites in poultry, and 
vaccines and feed additives for livestock and 
poultry 
Merck Animal 
Health 
Animal health companies manufactures vaccines, anti-infective and anti-
parasitic drugs, fertility management drugs and 
other specialty pharmaceutical products for 
companion animals and livestock 
Virbac Animal health companies manufactures antibiotics, vaccines, 
antiparasitics, dermatological and dental 
products for the treatment and care of pets and 
food animals 
Zoetis Animal health companies develops vaccines, parasiticides, anti-infectives, 
medicinal feed additives and drugs for pain, 
?sedation and cancers for pets and farm 
animals. 
 
Notes from the email responses and interviews are summarised below. 
HUMAN HEALTH 
6.1.1 CILAG (JOHNSON & JOHNSON) 
Ralf Schmidt, Senior Director, Head of Consumer Business Development EMEA at Cilag. 
Cilag is the Consumer Health and Over the Counter Medicines group within Johnson & Johnson 
• Ralf found the proposed approach surprising, because as highly priced drugs which are 
delivered by infusion, Enbrel or Remicade are not the type of treatment that springs to mind 
for a consumer health business. 
• The products that they are involved with are almost exclusively self-medications. 
• Digestive health products are definitely of interest to the consumer health team. Not just 
constipation, also diarrhoea and acid reflux. They are interested in new pre- and pro-biotics. 
• For this type of product to work for them, they need a clear understanding of the cost 
proposition, and how it could be delivered from a practical perspective. 
Confidential 
 
t:   +44 (0) 203 176 0580 | +44 (0)131 221 6570 
w:  http://www.ip-pragmatics.com 45 | P a g e  
a:  47 Mount Pleasant, London, WC1X 0AE, UK | Forth House, 28 Rutland Square, Edinburgh, EH1 2BW, UK 
• Alternative routes of delivery, eg suppositories, oral delivery with delayed release, 
transdermal, are all possible within an OTC environment. Transdermal delivery requires 
small molecule drugs, and would not be effective for Enbrel. 
• He is not an expert in this market indication, but his impression is that the existing OTC 
medications for constipation are effective enough. 
• This approach appears to be too sophisticated for this type of condition. Cost is a particular 
issue. For OTC drugs, there would be insurmountable regulatory hurdles for this type of drug 
to be approved for self-medication. 
• He will discuss with his colleagues in the pharmaceutical division whether there is a sub-set 
of patients where there is an unmet medical need that might justify use of a high cost 
product given by infusion. 
Follow up email received after he consulted further with his colleagues: 
We have looked at the concept again with my colleagues, but came to conclude that we really 
cannot see it within the consumer healthcare area that we’re of course focused on from a 
perspective of developing new treatment/product solutions.  In addition to the obvious areas 
already discussed (administration route, cost, regulatory framework) there may also be important 
considerations from an ethical perspective given the typical side effect profile of this type of 
immunologically active substances – so there use for a condition like constipation would have to be 
carefully evaluated in that context. 
I will be passing your request on to a colleague at Janssen, our Pharma group, so that they can also 
take a look at your proposal / your questions from a prescription pharmaceutical perspective, and 
then get in touch with you as they see fit. 
No response has yet been received from Janssen, but any additional feedback will be passed on. 
6.1.2 AMGEN 
Michelle Fortin, Program Lead of Academic Collaborations  
Elizabeth (Ellie) Robertson, Business Development: 
Thank you for reaching out to Michelle with the University of Brighton’s partnering opportunity. The 
message was forwarded to me, as I help facilitate the internal evaluation of available partnering 
opportunities. Unfortunately, treatments for constipation are not within our strategy and focus, but 
thank you for thinking of Amgen as a potential partner. 
6.1.3 SANOFI 
Adam Keeney, Partnering, Immunology, Sanofi-Genzyme: 
This indication is out of scope for us, so I’m afraid I wouldn’t have much to offer in the discussion as I 
do not know this particular space well. 
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6.1.4 MERCK & CO (HUMAN HEALTH) 
Jose Freire, Immunology and Respiratory S&E Lead, MRL Business Development & Licensing: 
We appreciate you considering Merck. Unfortunately this falls outside of our scope of interest.  
6.1.5 PROFESSOR ROBIN SPILLER, CLINICIAN 
Professor Spiller is Professor of Gastroenterology at the Nottingham Digestive Diseases Centre and 
NIHR  Digestive Diseases and Hepatology  Biomedical Research Unit: 
While the data is interesting the idea of using TNFa antagonists at the cost of £1000 per treatment 
and significant risk of serious life threatening infection mean that this will never fly 
There are a host of new very safe alternative nonsystemic treatments recently developed e.g. 
linaclotide or in the pipeline including plecanantide and Tenapanor which are likely to be preferred. 
 
ANIMAL HEALTH 
6.1.6 MERCK ANIMAL HEALTH 
Peter Opdam, Director, Business Development - Europe at Merck Animal Health: 
Constipation in elderly animals is not an area of active interest.  But we’ve always been a company 
that, at least for specialty pharmaceuticals for companion animals, is opportunistic and we let the 
science drive our interests.  So it may be that we’ve not come across a compelling candidate and, as 
such, have not tried to assess this potential market. 
Below please find a summary of my colleagues’ initial thoughts: 
• Constipation is multifactorial – it can be due to pain on defecation, a blockage of some sort 
(including hairballs), lack of water, etc. 
• It is much more prevalent (or at least noticed) problem in cats than dogs. 
• In cats, megacolon can be an important cause. 
• Most importantly it is not an old age problem, but a middle age thing (average around 6 
years).  
• In cats we also see obstipation (which is constipation but even worse so the feces in the gut 
is all dried out and they literally cannot defecate). 
• The challenge is that constipation is a clinical sign and not a diagnosis so there are 
potentially different approaches to treatment depending on the underlying cause. 
• It would be a niche segment (comparable to anti-emetics?) but could be bigger because cats 
with megacolon require much more intensive treatment. 
• A biological approach would bring with it the advantage of infrequent administration – but 
on the other hand would not be really indicated if it is a cat with a hairball. 
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• Interesting as an approach but cost of the drug would be a concern. 
• We would need to explore this further e.g. with KOL. 
6.1.7 ELANCO 
Bruce Taillon, Director, External Innovation: 
I have reached out to some internal research colleagues for opinions but I am afraid that it will be 
hard to pin down a market size. GI issues in dogs is very idiopathic and they can range from chronic 
inflammation to “garbage can gut”.  
[If forced to estimate, I might guess at] a market size of $10m when you divide the number of dogs 
that might be constipated by the ones that get taken the vet for the condition.  
A big consideration will also be whether it flips the condition to loose bowels which is [not] very 
good for the pet/owner bond. 
6.1.8 BOEHRINGER INGELHEIM / MERIAL 
Boehringer Ingelheim’s animal health business merged with Merial in 2017 to create the second 
largest animal health organisation in the world. 
Ursula Fauth, Head of Global Licensing Animal Health: 
Thank you very much for bringing this opportunity to my attention.  I have forwarded the 
information to our team of experts who will meet once a month to discuss and assess opportunities 
such as this.  Since the last meeting has been earlier this week, I expect that I can get back to you 
towards the end of July. 
6.1.9 ZOETIS 
Rudiger Raue, Research Alliances EU: 
Thanks a lot for your email. I am very happy to talk to you, but please give me a week to liaise with 
our commercial people to get a better idea about the market size for such an opportunity. 
6.1.10 PHILIPPA YAM, VET 
Philippa Yam is a veterinarian with a specialism in small animal gastroenterology. 
• Idiopathic chronic constipation – v rare in dogs. Never saw a case. Only related constipation 
case was a dog that had eaten a lot of driveway gravel through playing catch where it was 
painful to pass faeces 
• Commonly seen in cats 
o Causes can be secondary – e.g. as a result of road traffic accidents 
o Also primary idiopathic – Hirschsprung’s disease – neuronal disorder – also seen 
in new born children (rare disease) 
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• Don’t know if it’s an issue in horses – will try and identify somebody to speak to 
• Management: 
o Laxatives are used very commonly – e.g. lactulose – same as for humans most 
likely 
o Also will look to improve the diet to ensure sufficient quantities of highly 
digestible fibre included 
o Also medical management using motility modifiers 
 Did use cisapride but it was hard to obtain (Note: This drug appears to have 
been shelved) 
 Also metachlopramide 
• Cats can end up with end stage constipation (obstipation) – option to resect colon – not 
common 
o Well accepted procedure that is very successful 
o Cat needs to be monitored after surgery to make sure it is faecally continent 
o Not sure how much it costs nowadays (caveat anyway is that there’s a huge 
difference in prices across the country, and whether this is done at private 
practice vs a vet institution) but will run into the £’000s (operation = subtotal 
colectomy for megacolon in cats) but most pet owners will be covered by pet 
insurance. 
Follow up information: 
Ms Yam supplied an old article she published on the topic in cats - the management of the condition 
has changed much since then.  
She also supplied a reference to a study looking at the use of probiotics for constipation, with the 
comment: “This looks interesting…cheaper than biologicals!” 
6.1.11 PROF BRUCE MCGORUM 
Professor in Equine Medicine at The Royal (Dick) School of Veterinary Studies and The Roslin 
Institute, Edinburgh University: 
• Constipation in horses not seen often 
• Possible use in post op ileus which is more common problem than constipation? 
(https://thehorse.com/116386/equine-postoperative-ileus-insights/) 
• Has forwarded to Zofia Lisowski (also Edinburgh University) who works on equine GI 
motility, in particular the influence of macrophages on GI motility 
(https://www.ncbi.nlm.nih.gov/pubmed/29281117) 
6.1.12 PROF ALEX GERMAN 
Liverpool Vet School, Liverpool University, with a specialism in GI vet medicine: 
As a quick heads up, there would be more potential for cats rather than dogs. Constipation is not 
that common in dogs and the causes are heterogeneous, with few being age-related.  Constipation is 
much more common in cats than dogs, with many being related to idiopathic megacolon. So, in 
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theory, a new therapy here might be interesting.  That said, it’s not an age-related condition so it’s 
unclear whether targeting TNF would be helpful. The pathogenetic mechanisms are not well 
established for megacolon in cats - and there has been very little active research on the condition for 
at least 20 years.  However, it’s not clearly an age-related change. 
So, in answer to the broad question as to whether the treatment would be a goer in the veterinary 
market, it might be in cats, but that’s a bit of a long shot.  It would first need more fundamental 
research into the causes of megaolcolon in cats before animal trials.  I’d be very happy to do that if 
someone would fund me! 
Further response in relation to mode of administration: 
Injections can be used for one-off therapy for patients attending a vet clinic However, megacolon is a 
long-term condition and would require home management.  With the exception of insulin (diabetic 
cats) there are no injectable drugs used in a home setting. 
So, if the drug had to be given by injection, that would count against it further as a viable therapy. 
6.1.13 OAK TREE VET SURGERY, EDINBURGH 
Malcolm Leitch, Vet in a private vet practice 
• Generally chronic constipation is seen secondary to other disease, e.g. renal disease 
• More commonly seen in cats – again usually as a result of another cause 
• Constipation can be a problem for older cats – don’t know if it would have the desired effect 
in this population of patients 
• Standard care would be to give laxatives: paraffin, lactulose, or a combination of paraffin + 
lactulose 
o Lactulose is v cheap – dosage for cats ~2-5ml day. Cost for 500ml = £12 
• Occasionally use Cisapride, but it is hard to obtain.  
o Cisapride needs to be specially compounded; Pack of 100 (lasts 50 days) would cost 
£60 
• For colectomy, Malcolm reckons it would cost anywhere between £500-1000. Cat would also 
require support post-op care (e.g. infection control, and likely to continue to be prescribed 
laxatives once the cat has recovered) 
o Generally would try to keep any cat that has had this procedure hydrated, and 
prescribed laxatives, to keep things moving, otherwise it may have to endure regular 
enemas 
• Injectable drugs are not a problem for cats – diabetic cats get injections BID. Also treatment 
for thrombosis is by injection. 
o Monthly injections can be done at the practice, but anything that needs to be given 
daily would be done by the owners at home generally 
o Oral medications are not easy to give to cats! 
• Regarding horses – see constipation in grass sickness but don’t know how relevant this 
treatment would be for them 
o Ileus – common in horses, though won’t be a chronic condition 
• Ileus also a big problem in rabbits and guinea pigs that are stressed and unwell – can be fatal 
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o Generally treat with NSAIDS or metachlopramide (motility agent) 
o People don’t spend as much on rabbits or guinea pigs as they do with cats 
6.2 KEY USER REQUIREMENTS 
The key messages arising from our primary research are: 
• For human health, the concept seems to fall between two different types of pharmaceutical 
intervention. Chronic constipation is generally seen as an indication that is not of interest to 
the large prescription medicine pharmaceutical companies, which view it as out of scope for 
them. It is of more interest to their consumer health divisions, but these are focused on over 
the counter (OTC) remedies, and for these products injectable products with high cost would 
never be possible either from a market acceptance or a regulatory standpoint. 
• We did not manage to obtain very much direct feedback from those involved with patient 
care. The feedback we did receive, however, was that there were existing treatments 
available or in the pipeline which are very safe and efficacious. Whilst the mechanistic 
concept was interesting, the costs and risks infection were considered to rule out use of the 
existing anti-TNF drugs as a viable option for this patient group. 
• There was a more open-minded attitude within animal health, where an injectable product 
was seen as less of a disadvantage, and there are clear unmet medical needs, particularly 
amongst cats. 
• However, the biggest problems (such as idiopathic megacolon in cats and ileus in horses) do 
not appear to be clearly linked to age, and so may be acting through a different mechanism 
from the one investigated by the team in their aged mouse model. 
• Cost was consistently raised as an issue in animal health, particularly as the common 
treatments, such as laxatives, are very cheap and often efficacious. 
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7 CONCLUSIONS & RECOMMENDATIONS 
There is a large market for treatments for constipation, which is dominated by cheap over the 
counter remedies. It is not a well-defined disease entity, but a general collection of symptoms, which 
makes it more difficult to develop therapeutics which will target all causes of the effects. Many 
patients self-medicate, and those that do seek medical help are generally treated with lifestyle 
changes initially, followed by laxatives, before progressing to prescription drugs. Existing drugs are 
viewed as effective, and the leading prescription therapy, linaclotide, is expected to reach 
blockbuster status in several territories. The drug used by the team at Brighton to exemplify their 
approach is a biologic, which is very expensive, must be given by infusion, and has a suppressive 
effect on the immune system as well as potential side-effect on the heart and kidneys. Use of this 
particular drug would therefore be likely to be reserved for a very small sub-set of patients for whom 
all other options have failed. 
Our investigations of the patent landscape, coupled with the limited response received from the 
pharmaceutical companies in our primary research suggest that although the market is large, it is 
not an area of high current research interest, which supports the feedback from the primary 
interviews that constipation is not a disorder with high unmet medical need. The responses obtained 
to date suggest that this is a therapeutic area which is of highest interest to the OTC segment. In 
order to enter this market, however, the team would need to identify an active ingredient with a 
long safety record, which is cheap and (probably) which can be given orally. Even if the existing 
biologic could be re-formulated for oral delivery, the side effects and immune suppressive activity of 
anti-TNF-α would make it very difficult to achieve regulatory clearance for an OTC medication. An 
alternative would be to identify other active ingredients with the desired therapeutic, delivery and 
safety profile. Some of the larger pharmaceutical companies offer research access to their 
compound libraries, so this could be a potential route to identify alternative drugs with anti-TNF 
activity. However, as the existing marketed drugs with this activity are all biologics, it is less likely 
that these libraries will contain useful molecules which could fit the profile needed. 
There is no IP protection currently in place surrounding the Brighton approach. This will be a 
significant drawback to partnering with a pharmaceutical company with the global reach needed to 
address this market. Patent protection is essential to allow medicines to compete and to justify the 
significant investment that is needed to identify and develop and new active molecule, and carry out 
clinical development work. However, there could be opportunities for IP protection from the 
identification of novel compounds; the patent landscape in the treatment of chronic constipation is 
not crowded. 
The opportunity for animal health seems more promising, but in this area the underlying causes of 
problematic constipation are varied, and may not be related to ageing. Further fundamental 
research is therefore likely to be needed to establish if the causal link identified in the mouse model 
is relevant to these conditions. 
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A SWOT analysis of the overall opportunity based on the research summarized in this report is given 
in the table below: 
STRENGTHS WEAKNESSES 
• Novel approach, that does not appear to be 
actively researched by others 
• Potential to be curative, rather than just treat the 
symptoms 
• Large market for treatment of constipation 
• Existing treatments are generally cheap, safe and 
efficacious 
• Exemplar treatment used by the team has 
drawbacks in terms of cost, route of administration 
and side effects 
• Early stage of development, and a new molecule is 
likely to be needed to enter this market 
• Regulatory hurdles for an OTC product are high 
• Little interest identified in pharmaceutical 
companies for new approaches to constipation 
OPPORTUNITIES THREATS 
• Additional data on the effectiveness of etanercept 
compared with OTC laxatives in the Brighton 
mouse model could help to demonstrate superior 
activity for this approach 
• Identification of small molecule anti-TNF drugs 
would open up the potential for OTC drugs 
• Lack of registered IP protection is likely to 
significantly impact on the ability to gain traction 
with pharmaceutical companies 
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APPENDIX 1: SELECTED COMPANY DETAILS 
ARDELYX INC. 
34175 Ardenwood Blvd., Ste. 200 
Fremont, CA 94555 
Tel: 510/745-1700 
Website: www.ardelyx.com 
Ardelyx focuses on non-systemic and reduced risk therapies. Tenapanor is a Phase 3 promising drug 
being studied for Constipation Predominant Irritable Bowel Syndrome. Results of two Phase 3 trial 
are expected in 2017. 
ASTELLAS PHARMA INC. 
2-5-1, Nihonbashi-Honcho 
Chuo-Ku 103-8411 
Tokyo, Japan 
Tel: +81-3-3244-3000 
Website: www.astellas.com 
Astellas Pharma is headquartered in Tokyo, Japan. Astellas has more than 17,000 employees 
worldwide. In November 2015, Astellas Pharma and U.S.-based Ironwood Pharmaceuticals released 
results of a Phase 3 trial of linaclotide conducted in Japan in adults with irritable bowel syndrome 
with constipation (IBS-C). The double-blind, placebo-controlled trial randomized 500 adults with IBS-
C in Japan. Following that, a new drug application (NDA) seeking approval of linaclotide for the 
treatment of adults with irritable bowel syndrome with constipation (IBS-C) in Japan was filed with 
the Japanese Ministry of Health, Labor and Welfare, in February 2016. 
ASTRAZENECA 
2 Kingdom St. 
London W2 6BD 
United Kingdom 
Tel: +44(0)20-7604-8000 
Website: www.astrazeneca.com 
AstraZeneca is a pharmaceutical and biologics company headquartered in the U.K. The company was 
established in 1985 as Zeneca Group, then merged with Astra USA and became AstraZeneca in 1999. 
It offers several therapies in the area of gastrointestinal medicine like omeprazole (Prilosec) supplied 
as delayed-release capsules administered orally. Elobixibat is a Phase 2 therapy studied for the 
treatment of constipation, predominantly Irritated Bowel Syndrome (IBS-C). 
SUCAMPO PHARMACEUTICALS INC. 
805 King Farm Blvd., Ste. 550 
Rockville, MD 20850 
Tel: 301/961-3400 
Website: www.sucampo.com 
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Sucampo is a biopharmaceutical company working in the area of gastroenterology and focused on 
areas of unmet and underserved needs. It has discovered and developed an approved 
pharmaceutical product, Amitiza (Lubiprostone), for treating irritable bowel syndrome with 
constipation in adults, chronic constipation, chronic idiopathic constipation in adults and opioid-
induced constipation. Lubiprostone is being studied for Pediatric Functional Constipation and is in 
Phase 2 developmental stage. 
SYNERGY PHARMACEUTICALS INC. 
420 Lexington Ave., Ste. 2012 
New York, NY 10170 
Tel: 212/297-0020 
Website: www.synergypharma.com 
Synergy Pharmaceuticals is engaged in the discovery and development of novel gastrointestinal 
therapies. Plecanatide is the first uroguanylin analog presently being studied for treating irritable 
bowel syndrome with constipation (IBS-C). Plecanatide is a PHM046C - Gastrointestinal Therapeutics 
and Diagnostics: Technologies and Global Markets Copyright © BCC Research, Wellesley MA USA, 
Website: www.bccresearch.com 182 peptide made up of 16 amino acids. It is the first therapy 
studied to replicate the function of uroguanylin, a naturally occurring human GI peptide. It works in 
the upper GI tract to stimulate digestive fluid movement and helps in regular bowel function. The 
company’s second uroguanylin analog, Dolcanatide, is being explored for ulcerative colitis. 
VALEANT PHARMACEUTICALS 
2150 St. Elzéar Blvd. West 
Laval, Quebec H7L 4A8 
Canada 
Tel: 800/361-1448 
Website: www.valeant.com 
Valeant Pharmaceuticals specializes in dermatology, eye health, gastrointestinal diseases and 
disorders, neurology and consumer healthcare. Xifaxan was approved by the FDA in 2015 for 
treatment of irritable bowel diseases with diarrhea. Following the acquisition of Salix 
Pharmaceuticals in 2015, Valeant entered a new therapeutic area, gastrointestinal disorders. Among 
Salix’s key products are Xifaxan 550 mg (indicated for irritable bowel syndrome with diarrhea and 
hepatic encephalopathy), Xifaxan 200 mg (traveler’s diarrhea), Relistor (opioid-induced constipation) 
and Uceris and Apriso (ulcerative colitis). Other GI products include Ruconest, Giazo, Moviprep, 
Osmoprep, Solesta, Fulyzaq, Deflux, Glumetza, Cycloset and Zegerid 
 
